SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q2 2024 vs. Q1 2024
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 24 | 22 | −2 |
| Shares | 3.34M | 3.13M | −212.5K (−6.4%) |
| Value | $15.2M | $9.69M | −$5.47M (−36.1%) |
New holders (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| First PREMIER Bank | 19,386 | $60.0K | 0.02% |
| Bank of America Corp | 165 | $511 | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Commodore Capital LP | 183,174 | $831.6K |
| Spectrum Wealth Counsel, LLC | 503 | $2.28K |
| Wells Fargo & Company | 61 | $277 |
| GWM Advisors LLC | 14 | $64 |